Apimeds welcomes fda draft guidance as catalyst for advancing apitox non-opioid pain program

Matawan, n.j.--(business wire)--apimeds pharmaceuticals us, inc. (nyse: apus) today welcomed the u.s. food and drug administration's (fda) newly released draft guidance on the development of non-opioid pain therapies, highlighting its potential to accelerate the company's lead program, apitox, for chronic osteoarthritis pain. the draft guidance, entitled “development of non-opioid analgesics for chronic pain, draft guidance for industry”, can be found here: https://www.fda.gov/regulatory-inform.
APUS Ratings Summary
APUS Quant Ranking